| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -51.1 | -29.9 |
| EPS (diluted, $ a share) | $-0.74 | $-0.50 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TYRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tyra Biosciences, Inc.: key numbers
- Share price
- $19.74Close, Nov 16
- Market cap
- $1.36B
- Shares outstanding
- 69.08MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tyra Biosciences, Inc.
All →Tyra Biosciences Financial Results
Tyra Biosciences reported third quarter 2026 financial results, highlighting a cash position of $700.5 million following a $400 million financing. The company is advancing its '3x3 strategy' for dabogratinib, including positive initial Phase 2 results in NMIBC and preparations for Phase 3 development.
“2026 has been a defining year for TYRA. With the initial results from SURF302 in the ablative setting, we believe dabogratinib has the potential to be the first oral FGFR3-selective inhibitor in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), reinforcing our conviction in the potential of precision FGFR3 inhibition to fundamentally change the treatment paradigm for patients.”
Todd Harris, PhD, President and Chief Executive Officer
“With a strengthened balance sheet following our $400 million financing, TYRA is entering its next phase of growth from a position of strength. We now have the financial resources to advance our dabogratinib 3x3 strategy through late-stage clinical development.”
Todd Harris, PhD, President and Chief Executive Officer
Tyra Biosciences Capital Raise of $400M
Tyra Biosciences entered into an underwriting agreement to raise approximately $400 million through the sale of 9,079,000 shares of common stock and 9,078,529 pre-funded warrants. The offering was led by RA Capital Management and includes participation from several institutional investors to fund the development of dabogratinib and other pipeline programs. The common stock is priced at $22.03 per share, with the offering expected to close on September 15, 2026.
- Value
- $400M
- Counterparty
- Jefferies LLC